This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsui, W. Articles by Jones, R. J. Search for Related Content PubMed PubMed Citation Articles by Matsui, W. Articles by Jones, R. J.

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Requests for reprints: William Matsui, Department of Oncology, Johns Hopkins University School of Medicine, CRB245, 1650 Orleans Street, Baltimore, MD 21231. Phone: 410-955-2808; Fax: 410-614-7279; E-mail: matsuwi{at}jhmi.edu.

Many agents are active in multiple myeloma, but the majority of patients relapse. This clinical pattern suggests most cancer cells are eliminated, but cells with the clonogenic potential to mediate tumor regrowth are relatively chemoresistant. Our previous data suggested that CD138⁺ multiple myeloma plasma cells cannot undergo long-term proliferation but rather arise from clonogenic CD138^neg B cells. We compared the relative sensitivity of these distinct cell types to clinical antimyeloma agents and found that dexamethasone, lenadilomide, bortezomib, and 4-hydroxycyclophosphamide inhibited CD138⁺ multiple myeloma plasma cells but had little effect on CD138^neg precursors in vitro. We further characterized clonogenic multiple myeloma cells and stained cell lines using the Hoechst side population and Aldefluor assays. Each assay identified CD138^neg cells suggesting that they possess high drug efflux capacity and intracellular drug detoxification activity. We also found that multiple myeloma cells expressing the memory B-cell markers CD20 and CD27 could give rise to clonogenic multiple myeloma growth in vitro and engraft immunodeficient nonobese diabetes/severe combined immunodeficient mice during both primary and secondary transplantation. Furthermore, both the side population and Aldefluor assays were capable of identifying circulating clonotypic memory B-cell populations within the peripheral blood of multiple myeloma patients. Our results suggest that circulating clonotypic B-cell populations represent multiple myeloma stem cells, and the relative drug resistance of these cells is mediated by processes that protect normal stem cells from toxic injury. [Cancer Res 2008;68(1):190–7]

This article has been cited by other articles:

				N-T Ngo, C Brodie, C Giles, D Horncastle, M Klammer, I A Lampert, A Rahemtulla, and K N Naresh The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome J. Clin. Pathol., November 1, 2009; 62(11): 1009 - 1015. [Abstract] [Full Text] [PDF]

				H. Ikeda, T. Hideshima, M. Fulciniti, R. J. Lutz, H. Yasui, Y. Okawa, T. Kiziltepe, S. Vallet, S. Pozzi, L. Santo, et al. The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo Clin. Cancer Res., June 15, 2009; 15(12): 4028 - 4037. [Abstract] [Full Text] [PDF]

				R. J. Jones, C. D. Gocke, Y. L. Kasamon, C. B. Miller, B. Perkins, J. P. Barber, M. S. Vala, J. M. Gerber, L. L. Gellert, M. Siedner, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma Blood, June 4, 2009; 113(23): 5920 - 5926. [Abstract] [Full Text] [PDF]

				K. D'Costa, D. Emslie, D. Metcalf, G. K. Smyth, A. Karnowski, A. Kallies, S. L. Nutt, and L. M. Corcoran Blimp1 is limiting for transformation in a mouse plasmacytoma model Blood, June 4, 2009; 113(23): 5911 - 5919. [Abstract] [Full Text] [PDF]

				R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S. [Abstract] [Full Text] [PDF]

				E. Carlotti, D. Wrench, J. Matthews, S. Iqbal, A. Davies, A. Norton, J. Hart, R. Lai, S. Montoto, J. G. Gribben, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone Blood, April 9, 2009; 113(15): 3553 - 3557. [Abstract] [Full Text] [PDF]

				H.-J. Kolb Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood, December 1, 2008; 112(12): 4371 - 4383. [Abstract] [Full Text] [PDF]

				A. J. Jakubowiak, M. Hari, T. Kendall, Y. Khaled, S. Mineishi, A. Al-Zoubi, M. S. Kaminski, and I. Maillard Elimination of CD20-Expressing Cells in Multiple Myeloma by Iodine I-131 Tositumomab (Bexxar(R)) Correlates with Response to Therapy Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 5176 - 5176. [Abstract]

				D. F. Jelinek Myeloma research goes 3D Blood, October 1, 2008; 112(7): 2600 - 2601. [Full Text] [PDF]

				J. Kirshner, K. J. Thulien, L. D. Martin, C. Debes Marun, T. Reiman, A. R. Belch, and L. M. Pilarski A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma Blood, October 1, 2008; 112(7): 2935 - 2945. [Abstract] [Full Text] [PDF]

				B. J. Taylor, J. Kriangkum, J. A. Pittman, M. J. Mant, T. Reiman, A. R. Belch, and L. M. Pilarski Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny Blood, September 1, 2008; 112(5): 1894 - 1903. [Abstract] [Full Text] [PDF]

				C. A. Huff and W. Matsui Multiple Myeloma Cancer Stem Cells J. Clin. Oncol., June 10, 2008; 26(17): 2895 - 2900. [Abstract] [Full Text] [PDF]